An Open-Label, Prospective Study of the Safety of Rituximab in Combination With Other Disease-Modifying Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Rituximab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms SUNDIAL
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2012 Planned end date changed from 1 Nov 2011 to 1 Dec 2012 as reported by ClincialTrials.gov.